Who are selexipag (Uptravi)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mounjaro, Incretin Effect, FLOLAN injection with reformulated diluent, VIP, Inhaled Epoprostenol and phenylephrine, Epalrestat,Mecobalamin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/selexipag-uptravi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

selexipag (Uptravi) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

selexipag (Uptravi) (selexipag (Uptravi)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: prostacyclin receptor agonist. Area: Cardiovascular.

phase 3 prostacyclin receptor agonist IP receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

selexipag (Uptravi) (selexipag (Uptravi)) — Actelion. Selexipag is a prostacyclin receptor agonist that acts as a selective IP receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
selexipag (Uptravi) TARGET	selexipag (Uptravi)	Actelion	phase 3	prostacyclin receptor agonist	IP receptor
Mounjaro	TIRZEPATIDE	Eli Lilly	marketed	Dual GIP/GLP-1 receptor agonist	GIP receptor and GLP-1 receptor	2022-01-01
Incretin Effect	Incretin Effect	University of Campania Luigi Vanvitelli	marketed	Incretin-based therapy (mechanism class)	GLP-1 receptor and/or GIP receptor
FLOLAN injection with reformulated diluent	FLOLAN injection with reformulated diluent	GlaxoSmithKline	marketed	Prostacyclin analog	Prostacyclin receptor (IP receptor)
VIP	VIP	Danish Headache Center	marketed	Neuropeptide agonist	VIP receptor (VPAC1/VPAC2)
Inhaled Epoprostenol and phenylephrine	Inhaled Epoprostenol and phenylephrine	University Health Network, Toronto	marketed	Prostacyclin analog with alpha-1 adrenergic agonist	Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor
Epalrestat,Mecobalamin	Epalrestat,Mecobalamin	Xiangya Hospital of Central South University	marketed	Prostacyclin analog + Cobalamin derivative combination	Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (prostacyclin receptor agonist class)

Actelion · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). selexipag (Uptravi) — Competitive Intelligence Brief. https://druglandscape.com/ci/selexipag-uptravi. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing